Everyone's investing in AI. Almost nobody's seeing results.

71% of businesses use generative AI. But only 11% of pharma organizations achieved enterprise-wide implementation. 68% say the main reason AI initiatives fail is neglecting data quality and governance early.

We identified 5 persistent problems killing AI adoption in pharma marketing. Here's Problem #1 and how to fix it.

The Problem: AI tools weren't built for pharma workflows.

Most AI platforms were designed for consumer brands. Fast approvals. Light compliance. Minimal legal review.

In pharma, every piece of content goes through MLR. Every claim needs substantiation. Every channel has different regulatory requirements. The AI tool that works for a DTC shoe brand falls apart the moment it hits FDA guidelines and multi-stakeholder approval workflows.

Your team spends more time wrestling with the tool than they would have doing the work manually.

The Solution: AI built with compliance in mind.

NovaNext was built for pharma compliance from day one.

Here's how it works:

🎯 Risk Scoring Every claim gets evaluated. High risk? Medium? Low? You know before it hits MLR.

🔄 Backup Plans Built In NovaNext doesn't just flag problems. It generates alternatives. Scenario A gets rejected? B and C are already drafted and ready.

⚡ Speed Without Risk Cut review cycles without cutting corners. Compliant alternatives ready in seconds, not weeks of back-and-forth.

The difference: Consumer AI tools force you to retrofit compliance. NovaNext builds it in from the start.

Ready to see it in action? Contact us at FutureNova Health.

Sources: pharmaphorum 2026, ZS CDIO survey Oct 2025, McKinsey 2025